RGEN - Repligen Stock: Still Quite Overvalued
2024-05-30 15:03:56 ET
Summary
- Repligen Corporation stock has dropped 15% since our initial analysis of the stock just over six months ago.
- The company has posted a couple of quarterly earnings reports since then, and the company's balance sheet is in solid shape.
- That said, Repligen has hit a growth hiccup, and company insiders have picked up selling shares recently.
- An updated analysis around Repligen follows in the paragraphs below.
Our initial look at Repligen Corporation ( RGEN ) was back in mid-December of last year. We concluded that article around this biologic manufacturer by stating RGEN looked clearly overvalued using several valuation metrics. The stock has dropped a bit over 15% since our initial analysis. The company has also posted a couple of quarterly earnings reports since then. This is a name that comes up from time to time within comments from Seeking Alpha followers. Has the verdict around RGEN changed over the past six months after the share pullback? An updated take around Repligen Corporation follows below....
Repligen Stock: Still Quite Overvalued